SecBot SecBot
PRESS-RELEASE ·Filed May 1, 2026

ARVN

Arvinas Inc.
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

FDA approval of VEPPANU is a major catalyst validating the PROTAC platform and providing a new revenue stream. Monitor for the announced third-party commercialization partner and initial sales figures post-launch. Given ARVN's low market cap (~$633M), upside potential is significant, but historical stock performance after positive news has been poor; consider profit-taking on initial pop if sustained.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$10.51
T+0 close · May 1, 2026 · via day close
Latest settled
−21.98%
T+60 · $8.20
Vs SPY
−25.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $10.51entry
  2. T+1 · 7mo ago +2.57%α +2.91% · $10.78
  3. T+5 · 6mo ago −3.04%α −5.39% · $10.19
  4. T+20 · 6mo ago −18.36%α −23.65% · $8.58
  5. T+60 · 4mo ago −21.98%α −25.05% · $8.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arvinas (ARVN) announced FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC therapy, for ER+/HER2- ESR1-mutated advanced breast cancer after prior endocrine therapy. The approval came ahead of the PDUFA date and is based on the VERITAC-2 trial showing a 43% reduction in risk of disease progression or death vs fulvestrant (HR 0.57). This transformative milestone validates the PROTAC platform and provides a new treatment option for a significant unmet need, though commercial execution and competition remain risks.

Key Facts

  • First FDA-approved PROTAC therapy (VEPPANU/vepdegestrant), approved ahead of June 5, 2026 PDUFA date
  • Indication: ER+/HER2- ESR1-mutated advanced or metastatic breast cancer after ≥1 line of endocrine therapy
  • VERITAC-2 Phase 3 trial (N=270 ESR1m) showed median PFS 5 months vs 2.1 months for fulvestrant (HR 0.57, p=0.0001)
  • Discovered by Arvinas, jointly developed with Pfizer; companies plan to select a third-party partner for commercialization
  • Arvinas and Pfizer share worldwide development costs, commercialization expenses, and profits

Financial Impact

Transformative for ARVN as first approved drug; no specific revenue guidance provided. Partnership with Pfizer limits upside but reduces risk. Commercial potential depends on market adoption and third-party collaboration.

revenuepipeline valuation

Risk Factors

  • Commercial execution risk; vepdegestrant may face competition from existing endocrine therapies and CDK4/6 inhibitors
  • Safety signals including QTc prolongation, liver enzyme elevations, and cytopenias could limit uptake
  • Dependence on Pfizer partnership and third-party selection for commercialization
  • Potential for slower-than-expected physician adoption or payer reimbursement challenges

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
62% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3286140

Track record

21 reports on ARVN

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
  2. Nov 3, 202613d ago 8-K Bearish 5/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
  4. Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
  5. Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
  6. Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
  7. May 12, 202626w ago 8-K Mixed 6/10 No price data
  8. May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
  9. May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
  10. May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 1, 2026